These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26307603)

  • 1. Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
    Linnebjerg H; Lam EC; Seger ME; Coutant D; Chua L; Chong CL; Ferreira MM; Soon D; Zhang X
    Diabetes Care; 2015 Dec; 38(12):2226-33. PubMed ID: 26307603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
    Zhang X; Lam ECQ; Seger ME; Coutant D; Chua L; Tan LH; Soon D; Linnebjerg H
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):556-563. PubMed ID: 28940840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects.
    Liu H; Wang F; Ji Y; Ma T; Li H; Linnebjerg H; Chua L; Tham LS; Yu Y
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1452-1459. PubMed ID: 34410042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
    Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
    Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
    Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
    Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus
    Bhatia A; Tawade S; Mastim M; Kitabi EN; Gopalakrishnan M; Shah M; Yeshamaina S; Gobburu J; Sahib M; Thakur D; Prasanna Kumar KM
    Acta Diabetol; 2018 May; 55(5):461-468. PubMed ID: 29453671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
    Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
    Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
    Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
    Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
    Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
    Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
    Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
    Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
    Feng W; Chen W; Jiang S; Du L; Zhu D
    Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.
    Chen W; Lu J; Plum-Mörschel L; Andersen G; Zijlstra E; He A; Xie T; Li L; Hao C; Gan Z; Heise T
    Diabetes Obes Metab; 2023 Dec; 25(12):3817-3825. PubMed ID: 37735841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus
    Wang Y; Zhou Y; Ding J; Li X; Guo F; Zhang J; Ding L
    Front Pharmacol; 2022; 13():962201. PubMed ID: 36091767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
    Yan X; Jiang S; Lou Y; Zhou Z
    Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR
    Byrd RA; Owens RA; Blackbourne JL; Coutant DE; Farmen MW; Michael MD; Moyers JS; Schultze AE; Sievert MK; Tripathi NK; Vahle JL
    Regul Toxicol Pharmacol; 2017 Aug; 88():56-65. PubMed ID: 28526658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.